Paratek Pharmaceuticals Inc.

NASDAQ:PRTK  
4.40
-0.08 (-1.79%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)215.89M
Current PEN/A
Forward PE N/A
2yr Forward PE 48.89
See more stats
Estimates Current Quarter
Revenue$35.36 Million
Adjusted EPS-$0.34
See more estimates
10-Day MA$4.74
50-Day MA$4.96
200-Day MA$6.54
See more pivots

Paratek Pharmaceuticals Inc. Stock, NASDAQ:PRTK

75 Park Plaza, 4th floor, Boston, Massachusetts 02116-3934
United States of America
Phone: +1.617.807.6600
Number of Employees: 197

Description

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.